The clinical impact of time to response in de novo accelerated‐phase chronic myeloid leukemia.

MLA

Ohanian, Maro, et al. “The Clinical Impact of Time to Response in de Novo Accelerated‐phase Chronic Myeloid Leukemia.” American Journal of Hematology, vol. 95, no. 10, Oct. 2020, pp. 1127–34. EBSCOhost, https://doi.org/10.1002/ajh.25907.

APA

Ohanian, M., Kantarjian, H. M., Shoukier, M., Dellasala, S., Musaelyan, A., Nogueras Gonzalez, G. M., Jabbour, E., Abruzzo, L., Verstovsek, S., Borthakur, G., Ravandi, F., Garcia, M. G., Tamamyan, G., Champlin, R., Pierce, S., Ferrajoli, A., Kadia, T., & Cortes, J. E. (2020). The clinical impact of time to response in de novo accelerated‐phase chronic myeloid leukemia. American Journal of Hematology, 95(10), 1127–1134. https://doi.org/10.1002/ajh.25907

Chicago

Ohanian, Maro, Hagop M. Kantarjian, Mahran Shoukier, Sara Dellasala, Arine Musaelyan, Graciela M. Nogueras Gonzalez, Elias Jabbour, et al. 2020. “The Clinical Impact of Time to Response in de Novo Accelerated‐phase Chronic Myeloid Leukemia.” American Journal of Hematology 95 (10): 1127–34. doi:10.1002/ajh.25907.